Voyager Therapeutics, Inc. (VYGR)

Import this data to Google Sheets with:

=jivedata("VYGR","financials")

Full statements spill as a table. For one cell: =jivedata("VYGR","Revenue") or =jivedata("VYGR","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

Voyager Therapeutics, Inc.

VYGR • CIK 0001640266

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Revenue from Contract with Customer, Excluding Assessed Tax	$250,008	$80,001	$40,374	$34,459
Operating Income (Loss)	$122,014	$-83,287	$-131,844	$-117,188
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$133,738	$-64,337	$-119,577	$-107,602
Income Tax Expense (Benefit)	$1,408	$665	$144	$126
Net Income (Loss) Attributable to Parent	$132,330	$-65,002	$-119,721	$-107,728
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	$132,501	$-65,361	$-119,282	$-107,928
Weighted Average Number of Shares Outstanding, Basic	43,020,747	57,667,543	58,691,136	60,207,148
Weighted Average Number of Shares Outstanding, Diluted	44,569,334	57,667,543	58,691,136	60,207,148
Research and Development Expense	$92,172	$127,368	$134,674	$118,461
General and Administrative Expense	$35,822	$35,920	$37,544	$33,186
Operating Expenses	$127,994	$163,288	$172,218	$151,647
Interest Income (Expense), Nonoperating, Net	$11,721	$18,328	$10,618	$7,936
Other Nonoperating Income (Expense)	$3	$622	$1,649	$1,650
Nonoperating Income (Expense)	$11,724	$18,950	$12,267	$9,586
OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax	$171	$-359	$439	$-200

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash and Cash Equivalents, at Carrying Value	$68,802	$71,367	$65,300	$35,769
Marketable Securities, Current	$162,073	$195,317	$131,147	$80,569
Property, Plant and Equipment, Net	$16,494	$14,314	$13,136	$11,194
Receivables, Net, Current	$80,150	$1,504	$1,761	$2,932
Restricted Cash, Noncurrent	—	$2,874	$2,736	$2,736
Contract with Customer, Asset, after Allowance for Credit Loss, Current	$3,341	$676	$151	$222
Marketable Securities, Noncurrent	—	$65,704	$5,244	$32,476
Prepaid Expense and Other Assets, Current	$5,318	$7,945	$4,328	$5,736
Operating Lease, Right-of-Use Asset	$13,510	$33,349	$28,478	$25,905
Assets, Current	$319,684	$276,809	$202,687	$125,228
Assets	$351,281	$393,050	$252,281	$197,753
Operating Lease, Liability, Noncurrent	$17,093	$36,499	$28,659	$25,691
Contract with Customer, Liability, Noncurrent	$32,359	$6,003	$6,003	$1,471
Liabilities	$114,961	$93,290	$56,200	$43,376
Accounts Payable, Current	$1,604	$3,996	$5,013	$1,614
Accrued Liabilities, Current	$16,823	$14,171	$12,098	$7,951
Operating Lease, Liability, Current	$3,200	$7,227	$7,840	$6,876
Contract with Customer, Liability, Current	$42,881	$24,394	$1,590	$244
Liabilities, Current	$64,508	$49,788	$26,541	$16,685
Common Stock, Value, Issued	$44	$55	$59	$61
Additional Paid in Capital	$497,506	$626,296	$641,895	$653,052
Accumulated Other Comprehensive Income (Loss), Net of Tax	$-48	$-407	$32	$-421
Retained Earnings (Accumulated Deficit)	$-261,182	$-326,184	$-445,905	$-498,315
Stockholders' Equity Attributable to Parent	$236,320	$299,760	$196,081	$154,377
Preferred Stock, Shares Authorized	5,000,000	5,000,000	5,000,000	5,000,000
Preferred Stock, Shares Issued	0	0	0	0
Common Stock, Shares Authorized	120,000,000	120,000,000	120,000,000	240,000,000
Common Stock, Shares, Issued	44,038,333	54,731,316	59,047,860	61,273,390

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$132,330	$-65,002	$-119,721	$-107,728
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$-30,079	$3,846	$-6,205	$-8,309
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$70,395	$74,241	$68,036	$36,457
Share-based Payment Arrangement, Noncash Expense	$11,153	$14,785	$14,787	$11,902
Depreciation	$4,441	$4,731	$4,060	$3,821
Operating Lease, Impairment Loss	—	$2,776	$2,776	$2,776
Accretion (Amortization) of Discounts and Premiums, Investments	$3,626	$7,969	$2,973	$1,797
Gain (Loss) on Disposition of Property Plant Equipment	$-178	$-510	$-141	$-167
Operating Lease, Right-of-Use Asset, Amortization Expense	—	—	$4,871	$5,068
Increase (Decrease) in Accounts Receivable	$80,150	$-78,646	$257	$1,258
Increase (Decrease) in Prepaid Expense and Other Assets	$-76	$2,627	$-3,617	$-4,046
Increase (Decrease) in Accounts Payable	$-962	$2,392	$1,017	$-190
Increase (Decrease) in Accrued Liabilities	$9,007	$-2,652	$-2,500	$-4,501
IncreaseDecreaseInOperatingLeaseLiability	$-2,833	$-3,320	$-7,227	$-7,637
Increase (Decrease) in Contract with Customer, Liability	$9,414	$-44,842	$-28,807	$-22,880
Net Cash Provided by (Used in) Operating Activities	$77,919	$-15,310	$-132,467	$-120,572
Payments to Acquire Property, Plant, and Equipment	$3,256	$3,521	$2,596	$847
Payments to Acquire Marketable Securities	$223,968	$465,685	$133,929	$89,990
Proceeds from Sale and Maturity of Marketable Securities	$85,581	$374,347	$261,971	$196,641
Net Cash Provided by (Used in) Investing Activities	$-141,643	$-94,859	$125,446	$105,804
Proceeds from Stock Options Exercised	$1,852	$388	$267	$457
Proceeds from Issuance of Common Stock	—	$93,473	$93,473	—
Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised	$672	$849	$549	$334
Net Cash Provided by (Used in) Financing Activities	$33,645	$114,015	$816	$6,459
Capital Expenditures Incurred but Not yet Paid	$14	$14	$427	$427

Jive Data

Google Sheets add-onSheets Account

Import this data to Google Sheets with:

=jivedata("VYGR","financials")

Full statements spill as a table. For one cell: =jivedata("VYGR","Revenue") or =jivedata("VYGR","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

Voyager Therapeutics, Inc.

VYGR • CIK 0001640266

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Revenue from Contract with Customer, Excluding Assessed Tax	$250,008	$80,001	$40,374	$34,459
Operating Income (Loss)	$122,014	$-83,287	$-131,844	$-117,188
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$133,738	$-64,337	$-119,577	$-107,602
Income Tax Expense (Benefit)	$1,408	$665	$144	$126
Net Income (Loss) Attributable to Parent	$132,330	$-65,002	$-119,721	$-107,728
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	$132,501	$-65,361	$-119,282	$-107,928
Weighted Average Number of Shares Outstanding, Basic	43,020,747	57,667,543	58,691,136	60,207,148
Weighted Average Number of Shares Outstanding, Diluted	44,569,334	57,667,543	58,691,136	60,207,148
Research and Development Expense	$92,172	$127,368	$134,674	$118,461
General and Administrative Expense	$35,822	$35,920	$37,544	$33,186
Operating Expenses	$127,994	$163,288	$172,218	$151,647
Interest Income (Expense), Nonoperating, Net	$11,721	$18,328	$10,618	$7,936
Other Nonoperating Income (Expense)	$3	$622	$1,649	$1,650
Nonoperating Income (Expense)	$11,724	$18,950	$12,267	$9,586
OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax	$171	$-359	$439	$-200

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash and Cash Equivalents, at Carrying Value	$68,802	$71,367	$65,300	$35,769
Marketable Securities, Current	$162,073	$195,317	$131,147	$80,569
Property, Plant and Equipment, Net	$16,494	$14,314	$13,136	$11,194
Receivables, Net, Current	$80,150	$1,504	$1,761	$2,932
Restricted Cash, Noncurrent	—	$2,874	$2,736	$2,736
Contract with Customer, Asset, after Allowance for Credit Loss, Current	$3,341	$676	$151	$222
Marketable Securities, Noncurrent	—	$65,704	$5,244	$32,476
Prepaid Expense and Other Assets, Current	$5,318	$7,945	$4,328	$5,736
Operating Lease, Right-of-Use Asset	$13,510	$33,349	$28,478	$25,905
Assets, Current	$319,684	$276,809	$202,687	$125,228
Assets	$351,281	$393,050	$252,281	$197,753
Operating Lease, Liability, Noncurrent	$17,093	$36,499	$28,659	$25,691
Contract with Customer, Liability, Noncurrent	$32,359	$6,003	$6,003	$1,471
Liabilities	$114,961	$93,290	$56,200	$43,376
Accounts Payable, Current	$1,604	$3,996	$5,013	$1,614
Accrued Liabilities, Current	$16,823	$14,171	$12,098	$7,951
Operating Lease, Liability, Current	$3,200	$7,227	$7,840	$6,876
Contract with Customer, Liability, Current	$42,881	$24,394	$1,590	$244
Liabilities, Current	$64,508	$49,788	$26,541	$16,685
Common Stock, Value, Issued	$44	$55	$59	$61
Additional Paid in Capital	$497,506	$626,296	$641,895	$653,052
Accumulated Other Comprehensive Income (Loss), Net of Tax	$-48	$-407	$32	$-421
Retained Earnings (Accumulated Deficit)	$-261,182	$-326,184	$-445,905	$-498,315
Stockholders' Equity Attributable to Parent	$236,320	$299,760	$196,081	$154,377
Preferred Stock, Shares Authorized	5,000,000	5,000,000	5,000,000	5,000,000
Preferred Stock, Shares Issued	0	0	0	0
Common Stock, Shares Authorized	120,000,000	120,000,000	120,000,000	240,000,000
Common Stock, Shares, Issued	44,038,333	54,731,316	59,047,860	61,273,390

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$132,330	$-65,002	$-119,721	$-107,728
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$-30,079	$3,846	$-6,205	$-8,309
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$70,395	$74,241	$68,036	$36,457
Share-based Payment Arrangement, Noncash Expense	$11,153	$14,785	$14,787	$11,902
Depreciation	$4,441	$4,731	$4,060	$3,821
Operating Lease, Impairment Loss	—	$2,776	$2,776	$2,776
Accretion (Amortization) of Discounts and Premiums, Investments	$3,626	$7,969	$2,973	$1,797
Gain (Loss) on Disposition of Property Plant Equipment	$-178	$-510	$-141	$-167
Operating Lease, Right-of-Use Asset, Amortization Expense	—	—	$4,871	$5,068
Increase (Decrease) in Accounts Receivable	$80,150	$-78,646	$257	$1,258
Increase (Decrease) in Prepaid Expense and Other Assets	$-76	$2,627	$-3,617	$-4,046
Increase (Decrease) in Accounts Payable	$-962	$2,392	$1,017	$-190
Increase (Decrease) in Accrued Liabilities	$9,007	$-2,652	$-2,500	$-4,501
IncreaseDecreaseInOperatingLeaseLiability	$-2,833	$-3,320	$-7,227	$-7,637
Increase (Decrease) in Contract with Customer, Liability	$9,414	$-44,842	$-28,807	$-22,880
Net Cash Provided by (Used in) Operating Activities	$77,919	$-15,310	$-132,467	$-120,572
Payments to Acquire Property, Plant, and Equipment	$3,256	$3,521	$2,596	$847
Payments to Acquire Marketable Securities	$223,968	$465,685	$133,929	$89,990
Proceeds from Sale and Maturity of Marketable Securities	$85,581	$374,347	$261,971	$196,641
Net Cash Provided by (Used in) Investing Activities	$-141,643	$-94,859	$125,446	$105,804
Proceeds from Stock Options Exercised	$1,852	$388	$267	$457
Proceeds from Issuance of Common Stock	—	$93,473	$93,473	—
Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised	$672	$849	$549	$334
Net Cash Provided by (Used in) Financing Activities	$33,645	$114,015	$816	$6,459
Capital Expenditures Incurred but Not yet Paid	$14	$14	$427	$427

Voyager Therapeutics, Inc.

Statement Consolidated Statements of Operations and Comprehensive Loss Income

Statement Consolidated Balance Sheets

Statement Consolidated Statements of Cash Flows

Voyager Therapeutics, Inc.

Statement Consolidated Statements of Operations and Comprehensive Loss Income

Statement Consolidated Balance Sheets

Statement Consolidated Statements of Cash Flows